Inactive Instrument

Company Elanix Biotechnologies AG

Equities

ELN

DE000A0WMJQ4

Biotechnology & Medical Research

Business Summary

Elanix Biotechnologies AG is a Germany-based provider of solutions for tissue regeneration. The Company develops and commercializes products for acute wound care, dermatological and gynecological applications, and also provides cell technology services. It develops bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts. The Company's product portfolio comprises Gyn-RepAir cream, which contains a Cell Free Protein Complex (CFPC), and which includes various proteins such as collagen and fibronectin, as well as RepAir-A N cream. The Company also produces validated progenitor skin cells used in drug discovery, toxicity testing and cosmetic applications. It is a spin-out from the University Hospital of Lausanne (CHUV) in Switzerland.

Number of employees: 11

Managers

Managers TitleAgeSince
Chief Executive Officer - 11-12-31
Director of Finance/CFO - 18-05-28
Chief Tech/Sci/R&D Officer - -
Public Communications Contact - -

Members of the board

Members of the board TitleAgeSince
Chairman - 20-02-26
Director/Board Member - 21-05-03
Director/Board Member - 23-02-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 8,080,902 3,264,982 ( 40.40 %) 0 40.40 %

Company contact information

Elanix Biotechnologies AG

Hanauer Landstrasse 291 B

60314, Frankfurt

+

http://www.elanix-biotechnologies.de
address Elanix Biotechnologies AG(ELN)